Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is a potent -cell mitogen, and also stimulates insulin synthesis and secretion
At Evolve, we offer the following options for IV therapy: NAD IV & NAD IM: A powerful option for chronic fatigue, low energy, and pain management
This structural characteristic is reflected by an intense maximum spectral Band II and only a weak shoulder for Band I
And that weirdness catches most people completely off guard because they don't know what to eat or how much to eat when their body suddenly doesn't work the way it used to
In summary, based on preclinical and clinical studies, the addition of a dual GLP-1/GIP receptor agonist like CT-868 to insulin therapy for the treatment of T1D in patients with overweight or obesity could offer significant benefits in terms of improved glycemic control, reduced insulin doses, and weight loss, while also likely having a favorable safety and tolerability profile due to its intentional signaling bias
These numbers come from compounding pharmacy protocols and researcher-practitioner consensus, not FDA-reviewed clinical trials